XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies. Kruer TL, Quintana A, Newman H, Ferrall-Fairbanks M, et al. Blood 2025;146:2244-2258.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kruer TL, Quintana A, Newman H, Ferrall-Fairbanks M, et al. XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies. Blood 2025;146:2244-2258.
PMID: 40737597